Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx
Two Pharmaceutical Giants to Offer Discounted Medications on TrumpRx Website
In an exclusive report by CBS News, it has been revealed that two major drug manufacturers, Abbvie and Genentech, will soon begin selling popular commercial medications on the White House’s discounted pharmaceutical site, known as TrumpRx. This move comes as part of the Trump administration’s efforts to lower prescription drug prices and make essential medications more affordable for Americans.
Abbvie, in collaboration with the Trump administration, will be offering Humira at an 86% discount on the TrumpRx website. Humira is a widely-used medication for conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. This discount will be especially beneficial for uninsured individuals or those whose insurance does not cover the cost of the medication.
Genentech, another prominent pharmaceutical company, has also partnered with the White House to provide their prescription drug, Xofluza, at a reduced rate on the TrumpRx platform. This single dose pill is used for the treatment and prevention of the flu, and the discounted price will make it more accessible to those in need.
Additionally, Amgen will be expanding its offerings on the TrumpRx website to include Enbrel, a medication for arthritis, and Otezla, used to treat plaque psoriasis. With these new additions, TrumpRx now offers a total of 61 drugs at lower prices, demonstrating the administration’s commitment to making healthcare more affordable for all Americans.
The Trump administration’s approach to lowering prescription drug prices includes implementing “most-favored-nation” agreements, where pharmaceutical companies sell medications to uninsured individuals in the U.S. at prices comparable to those in other countries. This initiative aims to level the playing field and ensure that essential medications are accessible to all Americans.
Great Healthcare Plan and Future Prospects
The administration is currently working to solidify the discount prescription deals with the Great Healthcare Plan, which would allow individuals on government insurance to use copays for TrumpRx drugs. While Congress has yet to take up the Trump-proposed plan, the White House remains optimistic about the potential benefits it could bring to patients across the country.
With the addition of Abbvie, Genentech, and other pharmaceutical companies to the TrumpRx platform, more Americans will have access to essential medications at discounted prices. This initiative marks a significant step towards making healthcare more affordable and accessible for all, aligning with the administration’s commitment to putting patients first.
